New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:12 EDTFRX, AZN, IRWDIronwood reports Q4 LINZESS net product sales $51M, as reported by Forest
Ironwood (IRWD) says LINZESS net product sales, as reported by Forest Laboratories (FRX) were $51M in Q4, an increase of approximately 48% quarter over quarter, and $118.8M for the year ended December 31, 2013. More than 220,000 LINZESS prescriptions were filled in Q4, resulting in more than 24% growth in total prescriptions quarter over quarter, and over 580,000 LINZESS prescriptions were filled in 2013, according to IMS Health. In 2013, more than 50,000 healthcare practitioners prescribed LINZESS, including approximately 90% of high prescribing gastroenterologists and approximately 70% of other high prescribing healthcare practitioners, primarily primary care physicians. Physician prescribing continues to increase month over month. Almirall, S.A., Ironwood’s European partner, continues to launch CONSTELLA in Europe. CONSTELLA is currently available to adult IBS-C patients in nine countries in Europe, including the United Kingdom and Germany. Ironwood and AstraZeneca (AZN) continue to enroll patients in a Phase III clinical trial of linaclotide in adult patients with IBS-C in China. The trial is expected to be completed in the first half of 2015. Astellas Pharma Inc. has completed enrollment in a Phase II double-blind, placebo-controlled, dose-ranging clinical trial of linaclotide in adult patients with IBS-C in Japan.
News For IRWD;FRX;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
08:07 EDTIRWDIronwood initiates Phase I clinical study of IW-1973
Subscribe for More Information
March 4, 2015
10:01 EDTIRWDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:37 EDTIRWDIronwood initiated with an Equal Weight at Barclays
Target $18.
March 2, 2015
09:02 EDTAZNAstraZeneca mulls linking bonuses to Pfizer defense pledges, Sunday Times says
Subscribe for More Information
February 27, 2015
06:24 EDTAZNAstraZeneca turning antibiotic R&D into separate subsidiary, Reuters reports
Subscribe for More Information
February 23, 2015
12:53 EDTAZNAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
07:55 EDTAZNJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
February 20, 2015
07:23 EDTAZNAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTAZNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use